Following the Quintiles IMS Megamerger, which CRO will Enter the Healthcare Analytics Space Next?

Earlier this year a megamerger between Quintiles, the world’s largest CRO, and healthcare data and consultancy firm IMS was announced, with the combined company branded as Quintiles IMS. With a

Danaher Corporation Strengthens Diagnostics Offerings with $4B Acquisition of Cepheid

Danaher Corporation has announced the acquisition of medical diagnostics company Cepheid, strengthening their presence in the Molecular Diagnostics market. Danaher will pay $53 per share in cash, a premium of

Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?

Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation by Sanofi, as well

2016 US Venture Capital Investment into Life Sciences Companies: An Analysis by Evolution Bioscience

In order to elucidate the focus of Venture Capital funding in the Biotechnology sector this year, Evolution Analysts have assessed the deals carried out by the Top 25 US Venture

M&A Analysis: Bio-Techne enters Genomics market with $250M acquisition of Advanced Cell Diagnostics

Bio-Techne Corporation have agreed to acquire California-based molecular pathology company Advanced Cell Diagnostics for $250 million in cash plus additional potential milestone payments of up to $75M. The acquisition marks

Texcell acquisition of Vivo Science underscores the shifting Biopharma Contract Services landscape

Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunology & virology in vivo

Thermo Fisher to Acquire FEI Company for $4.2B

Thermo Fisher Scientific have further cemented their reputation as a serial acquirer with the purchase of FEI Company for approximately $4.2B in cash. Oregon-based FEI Company are world leaders in

Further AgriBusiness Consolidation as Bayer Makes a $62B Bid for Monsanto

Last week German multinational Bayer put forward an all-cash $62B bid for American AgTech giant Monsanto, further emphasizing the unprecedented period of consolidation that the global AgriBusiness market is currently

Cell Therapy Ltd grants Japanese Licence for its Heart Regeneration Medicine to Daiichi Sankyo

Welsh stem cell company Cell Therapy Ltd. has granted Japanese drugmaker Daiichi Sankyo a license for Heartcel™, its promising cardiac regeneration medicine. Under the conditions of the deal, Daiichi Sankyo

Evolution M&A Analysis: Evaluating Potential Acquisition Targets for Thermo Fisher Scientific

A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016

Evolution Infographic: The Rise & Diversification of Biologics

For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and

To CRISPR or not to CRISPR: The Ongoing Ethical Debate Surrounding Embryonic Gene Editing

The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of human embryos. The group,

Evolution Analysis: ACD Bio & Leica Biosystems Expand RNAscope Diagnostics Partnership

Advanced Cell Diagnostics and Leica Biosystems have announced a comprehensive partnership to develop and commercialise tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridisation (ISH) assays and Leica’s clinical